<DOC>
	<DOC>NCT00308737</DOC>
	<brief_summary>Pulmonary Safety in Diabetics with T/I</brief_summary>
	<brief_title>Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>For All Subjects: Nonsmoking Body mass index &lt;42 kg/m2 FEV1 greater than or equal to 70% of predicted , DLco and TLC greater than or equal to 80% of predicted at screening, No abnormalities in screening pulmonary radiology For Subjects with diabetes mellitus: Type 1 or type 2 diabetes for at least 2 years HbA1c greater than or equal to 6.6 % and less than or equal to 12.0 % For Subjects without abnormalities in glucose control: No history of diabetes Normal results from a formal glucose tolerance test History of chronic obstructive pulmonary disease, asthma, or other significant pulmonary disease Significant renal, hepatic, or cardiac disease Women who are pregnant, lactating, or planning on becoming pregnant Subjects who have participated in studies of other investigational drugs within the previous 3 months Evidence of severe complications of diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>